ATE169919T1 - Isolierung und struktur von spongistatin 5, 7, 8 und 9 und deren verwendung als antitumor-mittel - Google Patents

Isolierung und struktur von spongistatin 5, 7, 8 und 9 und deren verwendung als antitumor-mittel

Info

Publication number: ATE169919T1
Authority: AT; Austria
Prior art keywords: spongistatin; isolation; found; human cancer; tumor agent
Prior art date: 1993-07-02

Application number

AT94304809T

Other languages

English (en)

Inventor

George R Pettit

Zbigniew A Cichacz

Cherry L Herald

Original Assignee

Univ Arizona

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-02

Filing date

1994-06-30

Publication date

1998-09-15

1994-06-30 Application filed by Univ Arizona filed Critical Univ Arizona

1998-09-15 Application granted granted Critical

1998-09-15 Publication of ATE169919T1 publication Critical patent/ATE169919T1/de

Links

JOEPUFOWFXWEDN-UHFFFAOYSA-N Spongistatin 5 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-UHFFFAOYSA-N 0.000 title abstract 3
BTCJGYMVVGSTDN-UHFFFAOYSA-N Spongistatin 7 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 BTCJGYMVVGSTDN-UHFFFAOYSA-N 0.000 title abstract 3
GLMCWICCTJHQKE-UHFFFAOYSA-N Spongistatin 9 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-UHFFFAOYSA-N 0.000 title abstract 2
WYJXOZQMHBISBD-UHFFFAOYSA-N spongistatin 8 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 WYJXOZQMHBISBD-UHFFFAOYSA-N 0.000 title abstract 2
239000002246 antineoplastic agent Substances 0.000 title 1
238000002955 isolation Methods 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
241001465805 Nymphalidae Species 0.000 abstract 1
241000243142 Porifera Species 0.000 abstract 1
241000796716 Spirastrella Species 0.000 abstract 1
241000520664 Spongia Species 0.000 abstract 1
239000003966 growth inhibitor Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 abstract 1
HAOCRCFHEPRQOY-JKTUOYIXSA-N spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

AT94304809T 1993-07-02 1994-06-30 Isolierung und struktur von spongistatin 5, 7, 8 und 9 und deren verwendung als antitumor-mittel ATE169919T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/086,664 US5393897A (en)	1993-07-02	1993-07-02	Isolation and structure of spongistatins 5,7,8 and 9

Publications (1)

Publication Number	Publication Date
ATE169919T1 true ATE169919T1 (de)	1998-09-15

Family

ID=22200068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94304809T ATE169919T1 (de)	1993-07-02	1994-06-30	Isolierung und struktur von spongistatin 5, 7, 8 und 9 und deren verwendung als antitumor-mittel

Country Status (9)

Country	Link
US (1)	US5393897A (de)
EP (1)	EP0634414B1 (de)
JP (1)	JP3430322B2 (de)
AT (1)	ATE169919T1 (de)
CA (1)	CA2126910C (de)
DE (1)	DE69412551T2 (de)
DK (1)	DK0634414T3 (de)
ES (1)	ES2123714T3 (de)
MX (1)	MX9404999A (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5883120A (en) *	1997-06-16	1999-03-16	Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University	Antifungal activity of the spongistatins
WO1997048278A1 (en) *	1996-06-18	1997-12-24	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of The Arizona State University	Antifungal activity of the spongistatins
US5952376A (en) *	1997-11-07	1999-09-14	The Trustees Of The University Of Pennsylvania	Trienyl compounds
US6521661B1 (en)	2000-07-20	2003-02-18	Harbor Branch Oceanographic Institution, Inc.	Cyclic peroxides as novel antifungal agents
WO2002087423A2 (en) *	2001-05-02	2002-11-07	Blanchette Rockefeller Neurosciences Institute	Carbonic anhydrase activators for enhancing learning and memory
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
TW201207390A (en) *	2004-05-18	2012-02-16	Brni Neurosciences Inst	Method for screening agent for antidepressant activity
US20070054890A1 (en) *	2005-07-29	2007-03-08	Alkon Daniel L	Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
EP2762136A1 (de)	2006-07-28	2014-08-06	Blanchette Rockefeller Neurosciences, Institute	Verfahren zur Stimulierung von Zellwachstum, synaptischer Umformung und Verfestigung des Langzeitgedächtnisses
CN101848726A (zh)	2007-02-09	2010-09-29	布朗歇特洛克菲勒神经科学研究所	苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
ES2528033T3 (es)	2007-02-09	2015-02-03	Blanchette Rockefeller Neurosciences Institute	Efectos terapéuticos de las briostatinas sobre la alteración de la memoria inducida por isquemia/accidente vascular cerebral y lesiones cerebrales
US9053844B2 (en) *	2009-09-09	2015-06-09	Littelfuse, Inc.	Geometric configuration or alignment of protective material in a gap structure for electrical devices
EP2590642B1 (de)	2010-07-08	2018-03-14	Daniel L. Alkon	Pkc-aktivatoren und antikoagulans für einen therapieplan zur behandlung von apoplexie
JP6062362B2 (ja)	2010-08-19	2017-01-18	ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート	Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
WO2013071282A1 (en)	2011-11-13	2013-05-16	Blanchette Rockefeller Neurosciences Institute	Pkc activators and combinations thereof
US20180030095A1 (en)	2015-02-13	2018-02-01	George Robert Pettit	Silstatin compounds
US20180217163A1 (en)	2015-05-11	2018-08-02	Daniel L. Alkon	Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2019094709A1 (en)	2017-11-09	2019-05-16	Pettit George R	Betulastatin compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4164584A (en) *	1977-10-25	1979-08-14	Research Corporation	Anti-leukemic trichothecene epoxides
US4560774A (en) *	1982-11-17	1985-12-24	Arizona State University	Macrocyclic lactones
US4996229A (en) *	1985-06-06	1991-02-26	University Of Hawaii	Scytophycins
DE3669515D1 (de) *	1985-09-13	1990-04-19	Biotechnolog Forschung Gmbh	Makrozyklische antibiotika.
US4833257A (en) *	1986-07-28	1989-05-23	Arizona Board Of Regents	Compositions of matter and methods of using same
US4940726A (en) *	1989-04-26	1990-07-10	Arizona Board Of Regents	Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
US5436400A (en) *	1993-01-19	1995-07-25	Arizona Board Of Regents	Isolation and structure of spongistatin 1
US5328929A (en) *	1993-07-02	1994-07-12	Arizona Board Of Regents	Isolation and structure of spongistatin 2, spongistatin 3, spongistatin 4 and spongistatin 6

1993
- 1993-07-02 US US08/086,664 patent/US5393897A/en not_active Expired - Lifetime
1994
- 1994-06-28 CA CA002126910A patent/CA2126910C/en not_active Expired - Fee Related
- 1994-06-29 JP JP18173594A patent/JP3430322B2/ja not_active Expired - Fee Related
- 1994-06-30 DE DE69412551T patent/DE69412551T2/de not_active Expired - Fee Related
- 1994-06-30 EP EP94304809A patent/EP0634414B1/de not_active Expired - Lifetime
- 1994-06-30 ES ES94304809T patent/ES2123714T3/es not_active Expired - Lifetime
- 1994-06-30 MX MX9404999A patent/MX9404999A/es unknown
- 1994-06-30 AT AT94304809T patent/ATE169919T1/de not_active IP Right Cessation
- 1994-06-30 DK DK94304809T patent/DK0634414T3/da active

Also Published As

Publication number	Publication date
ES2123714T3 (es)	1999-01-16
CA2126910C (en)	2001-07-17
DE69412551T2 (de)	1999-02-04
DE69412551D1 (de)	1998-09-24
MX9404999A (es)	1995-01-31
EP0634414B1 (de)	1998-08-19
EP0634414A1 (de)	1995-01-18
CA2126910A1 (en)	1995-01-03
JP3430322B2 (ja)	2003-07-28
JPH07157428A (ja)	1995-06-20
US5393897A (en)	1995-02-28
DK0634414T3 (da)	1999-05-25

Similar Documents

Publication	Publication Date	Title
DE69412551D1 (de)	1998-09-24	Isolierung und Struktur von Spongistatin 5, 7, 8 und 9 und deren Verwendung als Antitumor-Mittel
GB2301363A (en)	1996-12-04	Human phosphodiesterase type ivc and its production and use
JPS57500830A (de)	1982-05-13
DE3484616D1 (de)	1991-06-27	Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE190355T1 (de)	2000-03-15	Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern
BR9507229A (pt)	1997-09-16	Amilase composição detergente aditivo detergente uso de um detergente e de uma amilase construç~o de dna vetor de expressão recombinante célula e processo para produzir amilase
DE69001458D1 (de)	1993-06-03	Mit einer benzotriazolgruppe substituierte diorganopolysiloxane enthaltende kosmetika sowie deren verwendung zum schutz von haut und haaren.
ATE347585T1 (de)	2006-12-15	In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
EA199900486A1 (ru)	1999-12-29	Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
HN1998000143A (es)	1999-04-09	Tetrahidronaftalenos substituidos y compuestos analogos.
Chen	1987	Factors influencing methane fermentation of micro-algae
ATE177472T1 (de)	1999-03-15	Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
EP0718858A3 (de)	1998-11-18	Verwendung von organischen Materialien hoher nichtionischer Ladungsträgerbeweglichkeit
WO1998037185A3 (en)	1998-11-26	Vectors for controlled gene expression
EA200100264A1 (ru)	2001-10-22	Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
ATE63111T1 (de)	1991-05-15	Substituierte oximether, ihre verwendung als bioregulatoren zur senkung des endogenen ethylenspiegels in pflanzen.
CA2126911A1 (en)	1995-01-03	Isolation and structure of spongistatin 2, spongistatin 3, spongistatin 4 and spongistatin 6
DE69410492D1 (de)	1998-07-02	Isolierung und Struktur von Spongistatin 1 und dessen Verwendung als Antitumor-Mittel
ATE236983T1 (de)	2003-04-15	Durch zelldichte stimulierte protein-tyrosin- phosphatasen
ATE148703T1 (de)	1997-02-15	Imidazoquinoxalinverbindungen, deren herstellung und verwendung
PT942978E (pt)	2003-01-31	Metodos para produzir o complexos promotor da anafase
DE3484422D1 (de)	1991-05-16	Verfahren zur herstellung von indanyl-derivaten und deren verwendung.
ATE200693T1 (de)	2001-05-15	Erhöhung der naphthalindioxygenase-wirkung während der mikrobiellen indigoherstellung
ES2129047T3 (es)	1999-06-01	Metodo para mejorar la memoria y la calidad de vida.
DE69941849D1 (de)	2010-02-04	Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen

Legal Events

Date	Code	Title	Description
1999-04-15	UEP	Publication of translation of european patent specification
2006-03-15	REN	Ceased due to non-payment of the annual fee